PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Nabilone - Nausea and vomiting (chemotherapy induced)

PAD Profile : Nabilone - Nausea and vomiting (chemotherapy induced)

Keywords :
cannabis-based medicinal products

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Capsules
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
CD
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
16 January 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey & North West Sussex Area Prescribing Committee (APC) recommends Nabilone for chemotherapy induced nausea & vomiting in adult patients and it will be considered RED on the traffic light system. 

Providers (NHS and non-NHS) will be solely liable for clinical governance, prescribing responsibility and costs of all prescriptions of nabilone when it is used off-label i.e. outside of its marketing authorisation. Shared care will not be supported for an off-label use of nabilone.

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.

Associated BNF Codes

04. Central Nervous System
04.06.00. Drugs used in nausea and vertigo
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More